Firat Selma, Elter Koray, Ateş Sinan, Fisunoğlu Mehmet
Department of Nutrition and Dietetics, Faculty of Health Sciences, Kırklareli University, Kırklareli 39100, Turkey.
Department of Obstetrics and Gynecology, Faculty of Medicine, Trakya University, Edirne 22030, Turkey.
Medicina (Kaunas). 2025 May 13;61(5):885. doi: 10.3390/medicina61050885.
: This study aimed to evaluate the impact of myoinositol (MYO) and α-lipoic acid (ALA) supplementation on hormonal and metabolic markers in women diagnosed with polycystic ovary syndrome (PCOS). : A retrospective case-control study was conducted with 58 women aged between 18-40 years who met the Rotterdam criteria for PCOS. The case group ( = 29) received MYO (2000 mg/day) and ALA (400 mg/day) supplements, while the control group ( = 29) did not receive any treatment. Data on the subjects' anthropometric measures, glycemic indices, sex hormones, and lipid profiles were collected. : The results demonstrated that, following three months of MYO + ALA supplementation, the case group exhibited steady body weight ( = 0.484) and BMI ( = 0.405), whereas the control group demonstrated a significant increase in both ( = 0.029; = 0.026, respectively). A stratified analysis based on BMI, waist circumference, and waist-to-height ratio revealed that HbA1c (%) was significantly lower in the "normal" subgroup compared to the "risky" subgroup within the case group ( < 0.05). Although the mean HbA1c, insulin, and HOMA-IR values were comparable between the two groups, the LH/FSH ratio significantly increased in the control group ( = 0.010). No significant differences were observed in the lipid profiles between the two groups; however, LDL levels decreased significantly in the case group ( = 0.024). Across all classifications, the "normal" subgroup consistently exhibited lower HbA1c and TG/HDL ratios than the "risky" subgroup. : Adding MYO + ALA supplementation to standard PCOS treatment may offer metabolic benefits, particularly in maintaining glycemic control, body weight, and BMI. Supplementation also reduces LDL.
本研究旨在评估补充肌醇（MYO）和α-硫辛酸（ALA）对诊断为多囊卵巢综合征（PCOS）的女性激素和代谢指标的影响。
进行了一项回顾性病例对照研究，纳入了58名年龄在18至40岁之间、符合鹿特丹PCOS标准的女性。病例组（n = 29）接受MYO（2000毫克/天）和ALA（400毫克/天）补充剂，而对照组（n = 29）未接受任何治疗。收集了受试者的人体测量指标、血糖指数、性激素和血脂谱数据。
结果表明，在补充MYO + ALA三个月后，病例组体重（P = 0.484）和BMI（P = 0.405）保持稳定，而对照组两者均显著增加（分别为P = 0.029；P = 0.026）。基于BMI、腰围和腰高比的分层分析显示，病例组中“正常”亚组的糖化血红蛋白（HbA1c）（%）显著低于“风险较高”亚组（P < 0.05）。尽管两组的平均HbA1c、胰岛素和HOMA-IR值相当，但对照组的LH/FSH比值显著升高（P = 0.010）。两组血脂谱无显著差异；然而，病例组的低密度脂蛋白（LDL）水平显著降低（P = 0.024）。在所有分类中，“正常”亚组的HbA1c和TG/HDL比值始终低于“风险较高”亚组。
在标准PCOS治疗中添加MYO + ALA补充剂可能具有代谢益处，特别是在维持血糖控制、体重和BMI方面。补充剂还可降低LDL。
